CHAPTER 1 INTRODUCTION

1.1 Key Benefits
1.2 Key Market Segment
1.3 Key Audiences
1.4 Research Methodology

1.4.1 Primary Research
1.4.2 Secondary Research
1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 MARKET OVERVIEW

3.1 Market Definition and Scope
3.2 Key Findings

3.2.1 Top factor impacting the market growth
3.2.2 Top investment pockets

3.3 Key market player positioning
3.4 Ebola Virus Key Facts

3.4.1 Transmission of Ebola
3.4.2 Signs and symptoms of ebola
3.4.3 Diagnosis of ebola
3.4.4 Vaccine or treatment available for ebola

3.5 Amend for anti-Ebola disease drugs in United States
3.6 Guidance on Air Medical Transport for Patients with Ebola Virus Disease
3.7 “Fast Track” designation to Anti-E bola drugs research from the U.S. government
3.8 ZMMP Drug: An Orphan solution for E-bola viral disease

3.8.1 ZMAPP is not ready for prime time

3.8.1.1 Orphan Drugs for Orphan Diseases

3.9 Ethical Dilemmas from therapeutics
3.10 Tekmira Pharma received boost to ebola R&D through FDA fundings
3.11 Clinical Trials
3.12 Market Dynamics

3.12.1 Drivers

3.12.1.1 Prevalent cases and unpredictable nature of disease
3.12.1.2 Increased rate of migration from developing countries
3.12.1.3 Lack of relevant medication

3.12.2 Restraints

3.12.2.1 High initial investment for R&D 
3.12.2.2 Obstractive ethical considerations

3.12.3 Opportunities

3.12.3.1 Development of economic vaccines and drugs
3.12.3.2 Gaining competitive edge in developing economies

CHAPTER 4 FORECASTE SCENARIO ANALYSIS OF EBOLA VACCINES, 2013-2020, ($MILLION)

4.1 Moderate growth scenario
4.2 Rapid growth scenario
4.3 Diminishing growth scenario

CHAPTER 5 GLOBAL PIPELINE AND MARKET POTENTIAL ANALYSIS OF E-BOLA THERAPEUTIC VACCINES MARKET BY GEOGRAPHY, 2013 – 2020

5.1 North America
5.2 Europe
5.3 Asia Pacific
5.4 LAMEA

CHAPTER 6 COMPANY PROFILES

6.1 Tekmira Pharmaceuticals

6.1.1 Overview
6.1.2 Company snapshot
6.1.3 Financial performance
6.1.4 Strategic moves and developments
6.1.5 SWOT analysis

6.2 BioCryst Pharmaceutical Inc.

6.2.1 Overview
6.2.2 Company snapshot of BioCryst Pharmaceutical Inc.
6.2.3 Financial performance
6.2.4 Strategic moves and developments
6.2.5 SWOT analysis

6.3 Serepata Therapeutics

6.3.1 Overview
6.3.2 Company snapshot
6.3.3 Strategic moves and developments
6.3.4 SWOT analysis

6.4 NewLink Genetics Corp.

6.4.1 Overview
6.4.2 Company snapshot
6.4.3 Financial performance
6.4.4 Strategic moves and developments
6.4.5 SWOT analysis

6.5 Mapp Biopharmaceutical

6.5.1 Overview
6.5.2 Company snapshot
6.5.3 Strategic moves and developments
6.5.4 SWOT analysis of Mapp Biopharmaceutical

LIST OF FIGURES

FIG. 1  TOP IMPACTING FACTORS OF EBOLA VIRAL DISEASE DRUGS (2013-2020)
FIG. 2  TOP INVESTMENT POCKETS
FIG. 3  KEY MARKET PLAYER POSITIONING OF EBOLA THERAPEUTICS
FIG. 4  MILESTONE OF E-BOLA DISEASE PREVALENCE BY GEOGRAPHIES
FIG. 5  SURGED EBOLA INCIDENCES IN WEST AFRICA (2014)
FIG. 6  TEKMIRA’S NET REVENUE FROM RESEARCH COLLABORATIONS AND CONTRACTS (2013)
FIG. 7  SWOT ANALYSIS OF TEKMIRA PHARMACEUTICALS
FIG. 8  R&D EXPENSES OF BIOCRYST PHARMACEUTICAL INC. (2013)
FIG. 9  SWOT ANALYSIS OF BIOCRYST PHARMACEUTICAL INC.
FIG. 10  SWOT ANALYSIS OF SEREPATA THERAPEUTICS
FIG. 11  RESEARCH AND DEVELOPMENT EXPENSES BY PRODUCTS (2013)
FIG. 12  SWOT ANALYSIS OF NEWLINK GENETICS CORP.
FIG. 13  SWOT ANALYSIS OF MAPP BIOPHARMACEUTICAL

LIST OF TABLES

TABLE 1  CHRONOLOGY OF E-BOLA VIRUS INCIDENCE
TABLE 2  CLINICAL TRIAL NO I
TABLE 3  CLINICAL TRIAL NO II
TABLE 4  CLINICAL TRIAL NO III
TABLE 5  RAPID GROWTH SCENARIO OF EBOLA VACCINES MARKET, 2013-2020 (THOUSAND UNIT)
TABLE 6  RAPID GROWTH SCENARIO OF EBOLA VACCINES MARKET, 2013-2020 ($THOUSAND)
TABLE 7  MODERATE GROWTH SCENARIO OF EBOLA VACCINES MARKET, 2013-2020 (THOUSAND UNIT)
TABLE 8  MODERATE GROWTH SCENARIO OF EBOLA VACCINES MARKET, 2013-2020 ($THOUSAND)
TABLE 9  DIMINISHING GROWTH SCENARIO OF EBOLA VACCINES MARKET, 2013-2020 (THOUSAND UNIT)
TABLE 10  DIMINISHING GROWTH SCENARIO OF EBOLA VACCINES MARKET, 2013-2020 ($THOUSAND)
TABLE 11  GLOBAL EVD POTENTIAL VACCINES MARKET BY GEOGRAPHY, 2015-2020, (THOUSAND UNITS)
TABLE 14  GLOBAL EVD VACCINES DEMAND BY GEOGRAPHY, 2015-2020, (UNITS IN THOUSAND)
TABLE 15  COMPANY SNAPSHOT OF TEKMIRA PHARMACEUTICALS
TABLE 16  COMPANY SNAPSHOT OF BIOCRYST PHARMACEUTICAL INC.
TABLE 17  COMPANY SNAPSHOT OF SEREPATA THERAPEUTICS
TABLE 18  COMPANY SNAPSHOT OF NEWLINK GENETICS CORP.
TABLE 19  COMPANY SNAPSHOT OF MAPP BIOPHARMACEUTICAL

The recent Ebola outbreak has raised questions about the safety and health of people living in Africa and other under-developed economies. These countries are facing problems due to continuous outbreaks of Ebola and also due to lack of effective medicinal solutions available in the market. Majority of African countries are badly affected by the deadly Ebola infection. The government healthcare services providers from these economies have failed to provide effective drugs and vaccines to the affected people. The reason behind this failure is the high cost of research and development and low profitability in terms of commercialization for the companies engaged in the manufacturing of novel therapeutics. In order to mitigate such issues several authorities from developed nations have taken initiatives in terms of funding and grants, providing momentum to the research and development of EVD therapeutics. This increase in the number of initiatives and funding has increased the probability of introducing novel vaccines and drugs in the future.